On May 20, 2025, ImmunityBio (IBRX, Financial) received a significant analyst upgrade from Piper Sandler, led by analyst Joseph Catanzaro. The stock's rating was raised from 'Neutral' to 'Overweight', signaling increased confidence in the company's prospects.
Alongside the rating upgrade, Piper Sandler also increased the price target for ImmunityBio (IBRX, Financial) from USD 4.25 to USD 5.00. This adjustment represents a 17.65% increase in the price target, suggesting a bullish outlook on the stock's performance.
Investors and market participants will be closely monitoring ImmunityBio (IBRX, Financial)'s movements in the market following these positive updates from a reputable analyst. This development may influence trading strategies and portfolio decisions related to ImmunityBio (IBRX) in the near term.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for ImmunityBio Inc (IBRX, Financial) is $11.40 with a high estimate of $30.00 and a low estimate of $5.00. The average target implies an upside of 300.91% from the current price of $2.84. More detailed estimate data can be found on the ImmunityBio Inc (IBRX) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, ImmunityBio Inc's (IBRX, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
